In 2007, patients who have Hodgkin's lymphoma, even in advanced stages, have a better than 85% chance of being cured of their disease if adequate therapy is given at the outset. Most ongoing or planned international studies tailor therapy according to the needs of the individual patient, also accounting for anatomic stage, tumor burden, age, gender, and biologic host factors that affect prognosis. With this approach it might be possible to use less aggressive treatment regimens for the lower-risk groups and limit the use of the more aggressive dose- and time-intensified/dense regimens for the higher-risk groups. With this individualized approach it might be possible to yield higher cure rates and simultaneously reduce the risk for late complications and mortality.